Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection

October 20, 2022

Peptilogics Presents Data Demonstrating Antimicrobial Activity Against Difficult to Treat Bacterial Pathogens of Engineered Peptide PLG0206 at the 2022 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

October 7, 2022

Peptilogics to Participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh

August 2, 2022

Peptilogics Receives FDA Fast Track Designation for PLG0206, an Investigational Peptide Therapeutic in Development for the Treatment of Periprosthetic Joint Infection

July 19, 2022

Orion Biotechnology and Peptilogics Enter Strategic Research Collaboration to Enable AI-Driven Drug Discovery Against Undrugged GPCR Target

July 12, 2022

Peptilogics to Present Data Highlighting Designed Antimicrobial Peptide for the Treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022

April 19, 2022

Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)

March 2022